News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
526,215 Results
Type
Article (32826)
Company Profile (77)
Press Release (493312)
Multimedia
Podcasts (32)
Webinars (9)
Section
Business (150865)
Career Advice (825)
Deals (25636)
Drug Delivery (60)
Drug Development (69196)
Employer Resources (69)
FDA (14196)
Job Trends (11066)
News (263710)
Policy (24767)
Tag
Academia (1965)
Accelerated approval (4)
Adcomms (13)
Allergies (82)
Alliances (35324)
ALS (72)
Alzheimer's disease (1094)
Antibody-drug conjugate (ADC) (81)
Approvals (14237)
Artificial intelligence (199)
Autoimmune disease (20)
Automation (8)
Bankruptcy (221)
Best Places to Work (8858)
BIOSECURE Act (5)
Biosimilars (54)
Biotechnology (61)
Bladder cancer (68)
Brain cancer (22)
Breast cancer (242)
Cancer (1877)
Cardiovascular disease (167)
Career advice (723)
Career pathing (15)
CAR-T (120)
Cell therapy (317)
Cervical cancer (20)
Clinical research (57777)
Collaboration (578)
Compensation (294)
Complete response letters (17)
COVID-19 (2268)
CRISPR (26)
C-suite (198)
Cystic fibrosis (72)
Data (2014)
Decentralized trials (2)
Denatured (17)
Depression (41)
Diabetes (233)
Diagnostics (4619)
Digital health (12)
Diversity (5)
Diversity, equity & inclusion (22)
Drug discovery (76)
Drug pricing (59)
Drug shortages (26)
Duchenne muscular dystrophy (82)
Earnings (62088)
Editorial (22)
Employer branding (11)
Employer resources (67)
Events (78998)
Executive appointments (604)
FDA (15388)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (7)
Funding (564)
Gene editing (74)
Generative AI (14)
Gene therapy (233)
GLP-1 (620)
Government (3549)
Grass and pollen (4)
Guidances (89)
Healthcare (15241)
Huntington's disease (20)
IgA nephropathy (23)
Immunology and inflammation (75)
Indications (26)
Infectious disease (2381)
Inflammatory bowel disease (117)
Inflation Reduction Act (6)
Influenza (36)
Intellectual property (65)
Interviews (88)
IPO (11904)
IRA (21)
Job creations (2566)
Job search strategy (665)
Kidney cancer (10)
Labor market (14)
Layoffs (275)
Leadership (8)
Legal (5131)
Liver cancer (66)
Lung cancer (280)
Lymphoma (130)
Machine learning (4)
Management (23)
Manufacturing (171)
MASH (70)
Medical device (13358)
Medtech (13362)
Mergers & acquisitions (14154)
Metabolic disorders (621)
Multiple sclerosis (67)
NASH (17)
Neurodegenerative disease (76)
Neuropsychiatric disorders (17)
Neuroscience (1540)
NextGen: Class of 2025 (4895)
Non-profit (3287)
Now hiring (19)
Obesity (332)
Opinion (116)
Ovarian cancer (68)
Pain (84)
Pancreatic cancer (68)
Parkinson's disease (123)
Partnered (16)
Patents (150)
Patient recruitment (111)
Peanut (42)
People (46390)
Pharmaceutical (20)
Pharmacy benefit managers (12)
Phase I (18673)
Phase II (25243)
Phase III (18708)
Pipeline (1114)
Policy (69)
Postmarket research (2172)
Preclinical (6122)
Press Release (68)
Prostate cancer (93)
Psychedelics (23)
Radiopharmaceuticals (204)
Rare diseases (300)
Real estate (4027)
Recruiting (23)
Regulatory (17904)
Reports (20)
Research institute (1830)
Resumes & cover letters (106)
Rett syndrome (5)
RNA editing (2)
RSV (32)
Schizophrenia (69)
Series A (92)
Series B (72)
Service/supplier (3)
Sickle cell disease (36)
Special edition (4)
Spinal muscular atrophy (136)
Sponsored (16)
Startups (2615)
Stomach cancer (10)
Supply chain (52)
Tariffs (18)
The Weekly (15)
Vaccines (618)
Venture capitalists (16)
Weight loss (223)
Women's health (20)
Worklife (4)
Date
Today (222)
Last 7 days (640)
Last 30 days (2188)
Last 365 days (25444)
2025 (8690)
2024 (27614)
2023 (31782)
2022 (41580)
2021 (44760)
2020 (42867)
2019 (36097)
2018 (27591)
2017 (25299)
2016 (24006)
2015 (28684)
2014 (22171)
2013 (18375)
2012 (19727)
2011 (20339)
2010 (19279)
Location
Africa (521)
Alabama (30)
Alaska (4)
Arizona (139)
Arkansas (10)
Asia (31205)
Australia (5062)
California (4675)
Canada (1598)
China (448)
Colorado (203)
Connecticut (212)
Delaware (138)
Europe (65279)
Florida (740)
Georgia (160)
Idaho (45)
Illinois (442)
India (19)
Indiana (266)
Iowa (4)
Japan (157)
Kansas (92)
Kentucky (21)
Louisiana (9)
Maine (65)
Maryland (777)
Massachusetts (3419)
Michigan (159)
Minnesota (349)
Mississippi (2)
Missouri (66)
Montana (28)
Nebraska (22)
Nevada (51)
New Hampshire (61)
New Jersey (1480)
New Mexico (14)
New York (1359)
North Carolina (794)
North Dakota (8)
Northern California (2103)
Ohio (156)
Oklahoma (8)
Oregon (28)
Pennsylvania (1086)
Puerto Rico (11)
Rhode Island (27)
South America (737)
South Carolina (24)
Southern California (1735)
Tennessee (87)
Texas (730)
United States (18159)
Utah (162)
Virginia (122)
Washington D.C. (48)
Washington State (361)
West Virginia (3)
Wisconsin (52)
526,215 Results for "dose medical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
-Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration
April 9, 2025
·
4 min read
glp-1
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
The data suggest the high dose nearly closes the efficacy gap with Zepbound.
January 17, 2025
·
3 min read
·
Nick Paul Taylor
Layoffs
Biogen Trims Research Workforce, Higher-Dose SMA Drug Accepted for Regulatory Review
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of its Ionis-partnered therapy Spinraza for spinal muscular atrophy will be considered by the FDA and EMA.
January 23, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
March 27, 2025
·
9 min read
Press Releases
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
March 20, 2025
·
3 min read
Press Releases
Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab
May 5, 2025
·
2 min read
Press Releases
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
April 1, 2025
·
12 min read
Press Releases
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
May 1, 2025
·
4 min read
Press Releases
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Phio’s Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration
December 19, 2024
·
4 min read
Press Releases
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
April 9, 2025
·
6 min read
1 of 52,622
Next
